A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

1. DCs pulsed with hypochlorous acid-treated tumor cell lysates present antigens efficiently and induce CD8Research in pharmaceutical sciences · 2025
   Article
2. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model.Cerebellum (London, England) · 2024
   Article
3. Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates.Pharmaceutics · 2022
   Review
4. Comparison of four methods of colon cancer cell lysates preparation forResearch in pharmaceutical sciences · 2022
   Article
5. ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?Vaccines · 2021
   Article
6. Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway.The FEBS journal · 2020
   Article
7. Antitumour dendritic cell vaccination in a priming and boosting approach.Nature reviews. Drug discovery · 2020
   Review
8. Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.Vaccines · 2020
   Article
9. IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine.Cancers · 2019
   Article
10. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Review
11. Dendritic cell engineering for selective targeting of female reproductive tract cancers.The Indian journal of medical research · 2018
    Review
12. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?Vaccines · 2018
    Review

Corrections and comments

• Erratum issued
  Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.2019 · Kandalaft L [corrected to Kandalaft LE]

Authors and funding

4 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as